US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 January 2015 The Indian Patent Office has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.
16 January 2015 The Indian Patent Office has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.
16 January 2015 The Indian Patent Office has rejected one of US drug maker Gilead’s patent applications to cover hepatitis C drug Sovaldi (sofosbuvir), in a decision that may decrease the blockbuster’s cost in the country.